ZNTL•benzinga•
Reported Saturday, Zentalis Presented Updated DENALI Part 1b Clinical Data Demonstrating 6.3-Month mDOR And ~35% ORR With Azenosertib Monotherapy In Cyclin E1+ Platinum-Resistant Ovarian Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 17, 2025 by benzinga